While Dubai captures headlines with its gleaming towers and luxury wellness centres, Abu Dhabi is quietly building something more foundational — a comprehensive health ecosystem designed to position the UAE as the world’s premier longevity hub. Backed by sovereign wealth, visionary healthcare groups, and a regulatory environment that embraces innovation, Abu Dhabi’s health authority push is reshaping how the Middle East approaches longevity science.
For investors, healthcare professionals, and individuals seeking the most advanced anti-aging care, understanding Abu Dhabi’s strategy is essential. This is where the future of longevity in the UAE is being engineered.
The Department of Health Abu Dhabi: Setting the Agenda
The Department of Health – Abu Dhabi (DoH) serves as the regulatory body overseeing the emirate’s healthcare sector, and its ambitions extend far beyond traditional medicine. In recent years, the DoH has actively promoted precision medicine, preventive health, and longevity research as strategic priorities.
Abu Dhabi’s Healthcare Sector Strategy 2026 explicitly identifies longevity medicine as a growth area, with dedicated funding for research partnerships, clinical infrastructure, and talent acquisition. The strategy aims to reduce the burden of chronic disease through early intervention and personalised health protocols — a core principle of modern longevity medicine.
Through its licensing framework, the DoH has also made it easier for international longevity practitioners to establish clinics in Abu Dhabi, creating a pipeline of world-class talent flowing into the emirate.
M42: Abu Dhabi’s Health Powerhouse
M42, the Abu Dhabi-based health group formed through the merger of G42 Healthcare and Mubadala Health, has emerged as one of the most significant players in the Middle East’s longevity landscape. With a mandate that spans AI-driven diagnostics, genomics, and population health, M42 is not just a healthcare provider — it is a longevity infrastructure builder.
Genomics and Precision Medicine
M42’s genomics division has sequenced hundreds of thousands of genomes through its population health programmes, creating one of the largest genetic databases in the Middle East. This data is being leveraged to develop personalised longevity protocols — identifying genetic predispositions to age-related diseases and tailoring interventions accordingly.
The integration of AI-powered biological age prediction into M42’s clinical workflows represents a significant advancement. Patients can now receive comprehensive biological age assessments that go far beyond chronological age, providing actionable insights for longevity optimisation.
AI and Health Analytics
M42’s partnership with technology powerhouses — including its deep integration with G42’s AI capabilities — gives it a unique advantage in health analytics. The group is developing predictive models that can identify health deterioration years before symptoms appear, enabling proactive intervention strategies that are central to longevity medicine.
This AI-first approach to healthcare aligns with Abu Dhabi’s broader vision of becoming a global AI hub, creating natural synergies between the technology and health sectors.
Abu Dhabi Global Market (ADGM): Where Fintech Meets Health Tech
One of Abu Dhabi’s most innovative contributions to the longevity ecosystem is the Abu Dhabi Global Market (ADGM), the emirate’s international financial centre. While primarily known for fintech regulation, ADGM has become an unexpected catalyst for health tech innovation.
Health Tech Sandboxes
ADGM’s regulatory sandbox framework allows health tech and longevity companies to test innovative products and services in a controlled environment before full market launch. This has attracted a wave of startups working on everything from tokenised health data platforms to AI-driven longevity scoring systems.
The intersection of fintech and health tech at ADGM is creating novel models for longevity financing — including health outcome-linked investment products and longevity insurance innovations that could transform how individuals fund their anti-aging programmes.
Digital Health Regulation
ADGM has also established a framework for regulating digital health platforms, telemedicine services, and health data management. For longevity companies operating across borders — serving clients in both Singapore and Abu Dhabi, for example — this regulatory clarity is invaluable.
Abu Dhabi’s Health Investment Landscape
Abu Dhabi’s sovereign wealth funds, particularly Mubadala Investment Company and the Abu Dhabi Investment Authority (ADIA), have been increasingly active in longevity-related investments globally. Mubadala’s healthcare portfolio alone exceeds $5 billion, with significant allocations to biotechnology, genomics, and regenerative medicine.
Key investment themes include:
- Regenerative medicine — Abu Dhabi is funding stem cell research centres and clinical application facilities
- Digital therapeutics — Investment in platforms that deliver evidence-based health interventions through software
- Longevity biotech — Direct investments in companies developing senolytic therapies, epigenetic reprogramming, and telomere extension technologies
- Health infrastructure — Building world-class hospital and clinic facilities designed for longevity medicine
The sheer scale of capital available in Abu Dhabi — combined with a willingness to take long-term bets on emerging health technologies — makes it one of the most important funding sources for the global longevity industry.
Research and Academic Excellence
Abu Dhabi’s investment in health research extends to its academic institutions. Khalifa University and NYU Abu Dhabi both host active research programmes in biomedical engineering, genomics, and aging biology. These institutions are producing peer-reviewed research on topics ranging from the molecular mechanisms of aging to the development of novel anti-aging compounds.
The Mohammed bin Rashid University of Medicine and Health Sciences (though Dubai-based, it operates across the UAE) has also established a longevity research division, further strengthening the UAE’s academic credentials in the field.
Connecting Abu Dhabi to the Global Longevity Network
Abu Dhabi’s health authority push is not happening in isolation. The emirate is actively building connections with the world’s leading longevity hubs — Singapore, Switzerland, Japan, and the United States. Bilateral health agreements, research partnerships, and talent exchange programmes are creating a global network with Abu Dhabi at a central node.
Premium longevity concierge services like Helix Privé are part of this global connectivity. By offering evidence-based longevity protocols that clients can access across multiple geographies, services like Helix Privé exemplify the borderless future of longevity medicine that Abu Dhabi is working to enable.
For executives and high-net-worth individuals who maintain residences or business interests in both Asia and the Middle East, this connectivity ensures continuity of care and access to the best longevity interventions regardless of location.
The Road Ahead: Abu Dhabi’s Longevity Vision
Abu Dhabi’s approach to longevity differs from Dubai’s in important ways. While Dubai leads with lifestyle, tourism, and clinical services, Abu Dhabi is building the deeper infrastructure — the research, the data, the capital, and the regulatory frameworks that will sustain the longevity industry for decades.
This complementary dynamic means that the UAE as a whole is exceptionally well-positioned. Abu Dhabi provides the engine; Dubai provides the showroom. Together, they are creating a longevity ecosystem that rivals — and in some areas surpasses — anything available in Singapore, Switzerland, or the United States.
For those in the longevity industry, Abu Dhabi is not just a market to watch. It is a market to engage with — whether as a researcher, investor, practitioner, or patient. The health authority’s push is real, funded, and accelerating.
FAQ
What is M42 and why does it matter for longevity?
M42 is Abu Dhabi’s flagship health group, formed from the merger of G42 Healthcare and Mubadala Health. It combines AI-driven diagnostics, one of the Middle East’s largest genomic databases, and clinical excellence to deliver precision medicine and longevity services at scale. Its integration of artificial intelligence into healthcare makes it a pioneer in predictive and preventive longevity medicine.
How is Abu Dhabi different from Dubai in its approach to longevity?
While Dubai focuses on clinical services, health tourism, and lifestyle wellness, Abu Dhabi invests more heavily in foundational infrastructure — research institutions, genomic databases, sovereign wealth-backed biotech investments, and regulatory innovation. Abu Dhabi builds the ecosystem; Dubai delivers the patient experience. Together, they create a comprehensive UAE longevity hub.
Can international patients access longevity treatments in Abu Dhabi?
Yes. Abu Dhabi’s Department of Health has streamlined licensing for international practitioners and welcomes medical tourists. The emirate offers advanced longevity treatments including genomic testing, NAD+ therapy, stem cell treatments, and AI-powered health assessments through facilities like those operated by M42.